AuditLine › HHS OIG › Centers for Medicare and Medicaid Services
HHS OIG recommendation 10-A-01-287.01
We recommended that Spectra Laboratories, a wholly owned subsidiary of Fresenius Medical Care North America (Fresenius), refund to the Medicare…
The recommendation, in the publisher's words
We recommended that Spectra Laboratories, a wholly owned subsidiary of Fresenius Medical Care North America (Fresenius), refund to the Medicare program $5.4 million in overpayments for CYs 2004�2006.
- Responsible agency
- Centers for Medicare and Medicaid Services
- Issued
- March 18, 2010
- Report
- Review of Separately Billed Laboratory Tests Submitted by Spectra Laboratories for Medicare Beneficiaries With End-Stage Renal Disease Receiving Dialysis at Fresenius Medical Care North America's Facilities (A-01-08-00511) · find it at HHS OIG
- Kind of report
- Audit
- Agency response
- Non-Concur (as recorded by the publisher)
- Closed
- February 10, 2022 (publisher's date)
- Potential savings
- $5,410,712 (the publisher's figure; not realised savings)
- Publisher topics
- Laboratories, Non-institutional care, Physician and Healthcare Practitioners
“Open” and “closed” are the publisher's words. AuditLine repeats them with the date it read them. It does not check whether a recommendation was carried out, and a closed recommendation is not proof that a problem was fixed.
Dated history
- Issued by HHS OIG. (publisher's date)
- Closed, with status “Closed Implemented”. (publisher's date)
- First recorded by AuditLine. (start of AuditLine's own history for this record)
- The publisher changed the recommendation's wording. (observed by AuditLine in the publisher's file)
Dates marked "publisher's date" come from the publisher's file. AuditLine's own observations begin November 10, 2026 and are added each time the publisher's file changes.
Source
Open this report in HHS OIG's tracker This publisher's records (CSV)
Official export: https://oig.hhs.gov/recommendations/export-recs/. File read , 4,677 rows,
SHA-256 664fdfb3658ecb72…. HHS OIG's status, response, dates and potential-savings labels are the publisher's own claims.